1. 346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors. (September 2015) Authors: Nayak, A.; Hao, Z.; Sadek, R.; Dobbins, R.; Marshall, L.; Vahanian, N.; Ramsey, J.; Kennedy, E.; Mautino, M.; Link, C.; Lin, R.; Royer-Joo, S.; Morrissey, K.; Mahrus, S.; McCall, B.; Pirzkall, A.; Munn, D.; Janik, J.; Khleif, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL). (12th June 2019) Authors: Sehn, L.H.; Assouline, S.; Bartlett, N.L.; Bosch, F.; Diefenbach, C.M.; Flinn, I.; Hong, J.Y.; Kim, W.S.; Matasar, M.; Nastoupil, L.; Schuster, S.J.; Shadman, M.; Yoon, S.S.; Bender, B.; Chu, W.; Hernandez, G.M.; Kwan, A.; McCall, B.; Sison, I.; Wang, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗